Basit öğe kaydını göster

dc.contributor.authorAidarova, Tamara
dc.contributor.authorOngen, Zeki
dc.contributor.authorGÜNDÜZ, HÜSEYİN
dc.contributor.authorKarakaya, Osman
dc.contributor.authorAvci, Burcak Kilickiran
dc.contributor.authorYuksel, Husniye
dc.contributor.authorVatan, Bulent
dc.contributor.authorTok, Ozge Ozden
dc.contributor.authorSahinkus, Salih
dc.contributor.authorUygun, Turgut
dc.date.accessioned2021-03-04T12:27:50Z
dc.date.available2021-03-04T12:27:50Z
dc.date.issued2016
dc.identifier.citationAvci B. K. , Vatan B., Tok O. O. , Aidarova T., Sahinkus S., Uygun T., GÜNDÜZ H., Karakaya O., Yuksel H., Ongen Z., "The Trends in Utilizing Nonvitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A Real-Life Experience", CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, cilt.22, sa.8, ss.785-791, 2016
dc.identifier.issn1076-0296
dc.identifier.otherav_776a6d14-1927-451f-b90f-429458c7737e
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/81988
dc.identifier.urihttps://doi.org/10.1177/1076029615581365
dc.description.abstractDabigatran and rivaroxaban are novel nonvitamin K antagonist oral anticoagulants (NOACs) approved for thromboprophylaxis in atrial fibrillation (AF). In Turkey, like other countries, the efficacy of translation of the clinical trial results and current guideline recommendations into daily clinical practice is yet to be discovered. Using data from medical records of three tertiary care cardiology centers, we identified patients with nonvalvular AF on dabigatran or rivaroxaban treatment. Baseline characteristics and utilization trends were compared between dabigatran and rivaroxaban groups. Secondarily, clinical events including ischemic stroke and/or transient ischemic attack, systemic embolism, and bleeding were evaluated. Among 294 patients with AF included, dabigatran was utilized in 177 (60.2%) and rivaroxaban in 117 (39.8%). Overall, 76% of patients had received long-term warfarin therapy. The use of 110 mg twice a day (55.4%) was the prevailing strategy in dabigatran group, whereas in rivaroxaban group 20 mg every day (67.5%) was the preferred option. Of the patients, 37.3% had severe valvular disease in which mitral regurgitation was the predominant valve abnormality. Scores of CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED were similar in both the groups. Of the patients, 24% in dabigatran group and 13.7% in rivaroxaban group were prescribed the lower dose inappropriately. The two NOACs did not differ significantly in terms of clinical events. The results of this study indicate that in daily practice, the physicians' behavior in utilizing the NOACs is shaped by the clinical trials and the guideline recommendations. On the other hand, in dose selection, this adherence is not of high quality.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectPERİFERAL VASKÜLER HASTALIĞI
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleThe Trends in Utilizing Nonvitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A Real-Life Experience
dc.typeMakale
dc.relation.journalCLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume22
dc.identifier.issue8
dc.identifier.startpage785
dc.identifier.endpage791
dc.contributor.firstauthorID236558


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster